PR Newswire: news distribution, targeting and monitoring
Home Page > News Releases > APAC > SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pfizer Inc. - PFE

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pfizer Inc. - PFE

2017-08-11 08:18
Share with Twitter

NEW YORK, Aug. 11, 2017 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Pfizer Inc. ("Pfizer" or the "Company") (NYSE:  PFE).   Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, Ext. 9980.

The investigation concerns whether Pfizer and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here to join a class action]

On August 10, 2017, post-market, Pfizer disclosed that the U.S. Justice Department is investigating the Company's Greenstone generics business, advising investors that "[w]e believe this is related to an ongoing antitrust investigation of the generic pharmaceutical industry."

The Pomerantz Firm, with offices in New York, Chicago, Florida, and Los Angeles, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com

CONTACT:
Robert S. Willoughby
Pomerantz LLP
rswilloughby@pomlaw.com

Source: Pomerantz LLP

Related stocks: NYSE:PFE

Featured Video

Recent Releases

Banking/Financial Service Recent Releases

Health Care/Hospital Recent Releases

Pharmaceuticals Recent Releases

Advanced Search
Search
  
  1. Products & Services
  2. News Releases
  3. Knowledge Center
  4. For Journalists & Media
  5. Multimedia Theater
  6. Contact Us